NCT06492850View on ClinicalTrials.gov

Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

February 1, 2026

Conditions
X-Linked Retinitis Pigmentosa (XLRP)
Interventions
GENETIC

FT-002

Intraocular injection of a single dose

Trial Locations (1)

100142

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Frontera Therapeutics

INDUSTRY

NCT06492850 - Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter